Single-dose pharmacokinetics and tolerability of telavancin in elderly men and women

Pharmacotherapy

Volumn 30, Issue 8, 2010, Pages 806-811

  Goldberg, Michael R ^a   Wong, Shekman L ^a   Shaw, Jeng Pyng ^a   Kitt, Michael M ^a   Barriere, Steven L ^a  

^a THERAVANCE INC   (United States)

Author keywords

Drug development; Elderly; Female; Male; Pharmacokinetics; Telavancin

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; TELAVANCIN;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; FEMALE; FLUSHING; HEADACHE; HUMAN; HUMAN EXPERIMENT; INJECTION SITE REACTION; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NORMAL HUMAN; OPEN STUDY; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PROTHROMBIN TIME; QT INTERVAL; SEX DIFFERENCE; SIDE EFFECT; SINGLE DRUG DOSE; URINE COMPOSITION DISORDER;

AGE FACTORS; AGED; AMINOGLYCOSIDES; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; SEX FACTORS;

EID: 77955455894     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.30.8.806     Document Type: Article

References (29)

1. Higgins DL, Chang R, Debabov DV, et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 2005;49:1127-34.
2. Pace JL, Krause K, Johnston D, et al. In vitro activity of TD-6424 against Staphylococcus aureus. Antimicrob Agents Chemother 2003;47:3602-4.
3. Stryjewski ME, O'Riordan WD, Lau WK, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis 2005;40:1601-7.
4. Stryjewski ME, Chu VH, O'Riordan WD, et al. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother 2006;50:862-7.
5. Stryjewski ME, Graham DR, Wilson SE, et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis 2008;46:1683-93.
6. Rubinstein E, Corey GR, Stryjewski ME, et al. Telavancin for hospital-acquired pneumonia, including ventilator-associated pneumonia: the ATTAIN studies [abstract 75]. Poster presented at the 18th European congress of clinical microbiology and infectious diseases, Barcelona, Spain, April 19, 2008. Clin Microbiol Infect 2008;14(s7):S14.
7. Shaw JP, Seroogy J, Kaniga K, Higgins DL, Kitt M, Barriere S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob Agents Chemother 2005;49:195-201.
8. Wong SL, Barriere SL, Kitt MM, Goldberg MR. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J Antimicrob Chemother 2008;62(4): 780-3.
9. Barriere S, Shaw JP, Seroogy J, Spencer E, Kitt M. Pharmacokinetics (PK) & safety of a new antibacterial, TD-6424 (TD), in healthy subjects [abstract A-20]. Presented at the 43rd annual interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 14-17, 2003.
10. Graham PL III, Lin SX, Larson EL. A U.S. population-based survey of Staphylococcus aureus colonization. Ann Intern Med 2006;144:318-25.
11. Kuehnert MJ, Kruszon-Moran D, Hill HA, et al. Prevalence of Staphylococcus aureus nasal colonization in the United States, 2001-2002. J Infect Dis 2006;193:172-9.
12. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillinresistant Staphylococcus aureus infections in the United States. JAMA 2007;298:1763-71.
13. Center for Drug Evaluation and Research. Guidance for industry: E6 good clinical practice: consolidated guidance, April 2006. Available from www.fda.gov/cder/guidance/ 959fnl.pdf. Accessed October 26, 2007.
14. Barriere S, Genter F, Spencer E, Kitt M, Hoelscher D, Morganroth J. Effects of a new antibacterial, telavancin, on cardiac repolarization (QTc interval duration) in healthy subjects. J Clin Pharmacol 2004;44:689-95.
15. Fridericia LS. The duration of systole in an electrocardiogram in normal humans and in patients with heart disease. Ann Noninvasive Electrocardiol 2003;8:343-51.
16. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
17. Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf 1999;20:109-17.
18. Hegde SS, Reyes N, Wiens T, et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against grampositive bacteria. Antimicrob Agents Chemother 2004;48(8): 3043-50.
19. King A, Phillips I, Kaniga K. Comparative in vitro activity of telavancin (TD-6424), a rapidly bactericidal, concentrationdependent anti-infective with multiple mechanisms of action against gram-positive bacteria. J Antimicrob Chemother 2004;53:797-803.
20. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States. Antimicrob Agents Chemother 2008;52(7):2383-8.
21. Jansen WT, Verel A, Verhoef J, Milatovic D. In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe. Antimicrob Agents Chemother 2007;51: 3420-4.
22. Draghi DC, Benton BM, Krause KM, Thornsberry C, Pillar C, Sahm DF. In vitro activity of telavancin against recent grampositive clinical isolates: results of the 2004-2005 prospective European surveillance initiative. J Antimicrob Chemother 2008;62(1):116-21.
23. Theravance, Inc. Data on file. South San Francisco, CA; 2006, 2008.
24. Samara E, Goldberg M, Shaw JP, et al. Population pharmacokinetics of telavancin in patients with complicated skin and soft tissue infections [abstract A-46]. Presented at the 47th annual interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
25. Samara E, Goldberg M, Shaw JP, et al. Population pharmacokinetics of telavancin in noninfected subjects [abstract A-45]. Presented at the 47th annual interscience conference on antimicrobial agents and chemotherapy, Chicago, IL, September 17-20, 2007.
26. Theravance, Inc. Data on file. South San Francisco, CA; 2006.
27. Turnheim K. Drug therapy in the elderly. Exp Gerontol 2004;39:1731-8.
28. Sun HK, Duchin K, Nightingale CH, Shaw JP, Seroogy J, Nicolau DP. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob Agents Chemother 2006;50:788-90.
29. Astellas Pharma Global Development Inc. and Theravance, Inc. VIBATIV prescribing information. Available from www.vibativ.com. Accessed December 14, 2009.